Linked Data API

Show Search Form

Search Results

1142432
star this property registered interest false more like this
star this property date less than 2019-07-25more like thismore than 2019-07-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading NHS: Pensions more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have, if any, to compensate senior NHS staff who have inadvertently exceeded the tapered annual pensions allowance. more like this
star this property tabling member printed
Baroness Altmann more like this
star this property uin HL17506 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>For the majority of people, their pension contributions are tax-free. This makes pensions tax relief one of the most expensive reliefs in the personal tax system. The reforms to the lifetime and annual allowance made in the previous two parliaments are expected to save over £6 billion per year and are necessary to deliver a fair system and protect public finances. Less than 1% of pension savers will have to reduce their saving or face an annual allowance charge as a result of the tapered annual allowance.</p><p>While there are no plans to compensate senior National Health Service staff who exceed their tax-free pension savings allowances, the Scheme Pays facility is there to assist NHS Pension Scheme members who breach the annual allowance, and allows them to settle their lifetime and annual allowance charges without making an upfront payment. The Scheme Pays facility was recently extended to cover tax charges of any amount and those arising from the tapered annual allowance.</p><p>The Government has launched a full public consultation setting out proposals to make the NHS Pension Scheme more flexible for clinicians, to give them more control over their pension growth and tax liabilities.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-08-06T15:06:30.857Zmore like thismore than 2019-08-06T15:06:30.857Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4533
unstar this property label Biography information for Baroness Altmann more like this
1141905
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Accident and Emergency Departments: Greater Manchester more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what were the average annual waiting times for each accident and emergency department in Greater Manchester in each of the last five years. more like this
star this property tabling member printed
Lord Bradley more like this
star this property uin HL17449 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-07more like thismore than 2019-08-07
star this property answer text <p>Data is not available in the format requested.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
remove maximum value filtermore like thismore than 2019-08-07T11:37:37.95Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
452
unstar this property label Biography information for Lord Bradley more like this
1141919
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Bacterial Diseases more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 9 July (HL16592), what is their view of the proportion of each of the resulting illness, deaths and costs that could be prevented by new efforts to prevent transmission; and what are the costs of new measures introduced in 2019 to prevent transmission of carbapenem-resistant Enterobacteriaceae. more like this
star this property tabling member printed
Baroness Gardner of Parkes more like this
star this property uin HL17463 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>Public Health England (PHE) has prioritised collecting the necessary data across the National Health Service to enable estimation and monitoring of the proportion of cases, deaths and costs attributable to carbapenemase-resistant Enterobacteriaceae.</p><p>In May 2015 PHE implemented an enhanced surveillance system of all carbapenemase-producing Gram negative bacteria, which was modified in 2019 to maximise efficiency. The health burden of cases, estimated from these data, will be published in the <em>English Surveillance Programme for Antimicrobial Utilisation Report</em> in November 2019.</p><p>The few published reports of outbreaks have estimated costs of at least £1 million, and up to £5 million, all indicating multi-model control measures are required, as outlined in the PHE toolkit for prevention and control of carbapenemase-producing Enterobacteriaceae which is currently being updated.</p><p>Using national surveillance and patient administration data to develop mathematical models, work is ongoing to estimate the reduction in levels of illness and death when specified detection and control measures are applied by 2020. Developed models will enable associated costs incurred to be estimated and the cost-effectiveness of control measures to be established by 2021.</p><p> </p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-08-06T15:07:02.27Zmore like thismore than 2019-08-06T15:07:02.27Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3596
unstar this property label Biography information for Baroness Gardner of Parkes more like this
1141940
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Gambling: Rehabilitation more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 17 July (HL16963 and HL16964), what was the budget of Leeds and York Partnership NHS Trust for funding the NHS Northern Gambling Clinic; and what is the projected cost of that clinic in (1) 2020, (2) 2021, and (3) 2022. more like this
star this property tabling member printed
The Lord Bishop of St Albans more like this
star this property uin HL17484 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>NHS England and NHS Improvement have allocated £600,000 to Central and North West London NHS Foundation Trust and £370,000 to Leeds and York Partnership NHS Foundation Trust for gambling harm services provision in 2019/20, which includes funding for these clinics.</p><p> </p><p>GambleAware, an independent charity, is providing additional funding for these clinics. Information on this funding is not held centrally.</p><p> </p><p>Future years’ funding is not yet available.</p><p> </p><p> </p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17485 more like this
star this property question first answered
less than 2019-08-06T14:58:10.86Zmore like thismore than 2019-08-06T14:58:10.86Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4308
unstar this property label Biography information for The Lord Bishop of St Albans more like this
1141941
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Problem Gambling Clinic more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 17 July (HL16963 and HL16964), what was the budget of the Central and North West London NHS Foundation Trust for funding the National Problem Gambling Clinic; and what is the projected cost of that clinic in (1) 2020, (2) 2021, and (3) 2022. more like this
star this property tabling member printed
The Lord Bishop of St Albans more like this
star this property uin HL17485 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>NHS England and NHS Improvement have allocated £600,000 to Central and North West London NHS Foundation Trust and £370,000 to Leeds and York Partnership NHS Foundation Trust for gambling harm services provision in 2019/20, which includes funding for these clinics.</p><p> </p><p>GambleAware, an independent charity, is providing additional funding for these clinics. Information on this funding is not held centrally.</p><p> </p><p>Future years’ funding is not yet available.</p><p> </p><p> </p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17484 more like this
star this property question first answered
less than 2019-08-06T14:58:10.893Zmore like thismore than 2019-08-06T14:58:10.893Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4308
unstar this property label Biography information for The Lord Bishop of St Albans more like this
1141957
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Breast Cancer: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL17501 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17502 more like this
star this property question first answered
less than 2019-07-25T16:45:03.16Zmore like thismore than 2019-07-25T16:45:03.16Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
1141958
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Pertuzumab more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL17502 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17501 more like this
star this property question first answered
less than 2019-07-25T16:45:03.207Zmore like thismore than 2019-07-25T16:45:03.207Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
1141251
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cancer: Health Services more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when a long-term workforce plan which sets out the number of staff required to meet the current and future needs of cancer patients will be published. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 280964 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-05more like thismore than 2019-08-05
star this property answer text <p>The interim NHS People Plan, published on 3 June 2019, puts the workforce at the heart of the National Health Service and will ensure we have the staff needed to deliver high quality care. A final People Plan will be published soon after the conclusion of the 2019 Spending Review.</p><p>Phase 1 of the Cancer Workforce Plan for England, published in December 2017 by Health Education England (HEE), set out plans to expand capacity and skills in the cancer workforce, including targeting additional training support for seven priority professions which are key to cancer prevention, diagnosis and treatment, such as clinical radiology, histopathology, oncology and diagnostic and therapeutic radiography.</p><p>HEE will now work with NHS England and NHS Improvement to understand the longer-term workforce implications of further development of cancer services. This work will inform the final People Plan.</p> more like this
star this property answering member constituency Bury St Edmunds more like this
star this property answering member printed Jo Churchill more like this
star this property question first answered
less than 2019-08-05T11:30:43.603Zmore like thismore than 2019-08-05T11:30:43.603Z
star this property answering member
4380
star this property label Biography information for Jo Churchill more like this
star this property tabling member
1506
unstar this property label Biography information for Andrew Gwynne more like this
1141253
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading NHS: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential effect of the UK leaving the EU on the supply of drugs to the NHS. more like this
star this property tabling member constituency Tooting more like this
star this property tabling member printed
Dr Rosena Allin-Khan more like this
star this property uin 281022 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-02more like thismore than 2019-08-02
star this property answer text <p>The United Kingdom will leave the European Union on 31 October, with or without a deal. The Government would prefer the UK to leave the EU with a deal and, in the event that the UK leaves the EU with a new deal, the Department’s assessment is that access to medicines and medical devices will not change for industry or the National Health Service.</p><p>While the Prime Minister is confident that he can strike a new arrangement with the EU, it is vital that we prepare for a ‘no deal’ outcome. Therefore, as a responsible Government, we continue to take steps to ensure the supply of medicines and medical products is uninterrupted in a ‘no deal’ scenario.</p><p>On 26 June, we wrote to suppliers of medicines to the UK from or via the EU or European Economic Area setting out our continuing multi-layered approach to ensure the continuity of supply of all medicines and medical products in a potential ‘no deal’ exit scenario on 31 October.</p><p>Further details can be found at the following link:</p><p><a href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans" target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a></p><p>Ahead of 31 October, all necessary funding will be made available to support our ‘no deal’ preparations. On 1 August, Her Majesty’s Treasury announced an additional £434 million made available to help ensure continuity of supply of vital medicines and medical products, including through freight capacity, warehousing and stockpiling.</p><p>We are confident that the Department is doing everything appropriate to prepare for a possible ‘no deal’ EU exit on 31 October. We are working with our partners, including suppliers, freight companies and the health and social care system and our plans should ensure the supply of medicines and medical products remains uninterrupted.</p>
star this property answering member constituency Kingswood more like this
star this property answering member printed Chris Skidmore more like this
star this property question first answered
less than 2019-08-02T09:59:35.05Zmore like thismore than 2019-08-02T09:59:35.05Z
star this property answering member
4021
star this property label Biography information for Chris Skidmore more like this
star this property tabling member
4573
unstar this property label Biography information for Dr Rosena Allin-Khan more like this
1141255
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Non-surgical Cosmetic Procedures: Children more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what legal duties govern the administering of dermal fillers to people under the age of 18 by non-regulated practitioners. more like this
star this property tabling member constituency North Durham more like this
star this property tabling member printed
Mr Kevan Jones more like this
star this property uin 280927 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Currently there are no restrictions that limit the administration of dermal fillers on young people under the age of 18 years old.</p><p>The Department is exploring options to introduce age restrictions on access to cosmetic procedures, bringing them in line with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p>
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:32:36.833Zmore like thisremove minimum value filter
star this property answering member
4065
star this property label Biography information for Dame Jackie Doyle-Price more like this
star this property tabling member
1438
unstar this property label Biography information for Mr Kevan Jones more like this